Local view for "http://wifo5-04.informatik.uni-mannheim.de/drugbank/resource/drugs/DB01819"
Predicate | Value (sorted: none) |
---|---|
owl:sameAs | |
owl:sameAs | |
owl:sameAs | |
owl:sameAs | |
owl:sameAs | |
owl:sameAs | |
owl:sameAs | |
owl:sameAs | |
rdf:type | |
owl:sameAs | |
rdfs:label |
"Phosphoenolpyruvate"
|
owl:sameAs | |
owl:sameAs | |
owl:sameAs | |
owl:sameAs | |
owl:sameAs | |
owl:sameAs | |
owl:sameAs | |
owl:sameAs | |
owl:sameAs | |
owl:sameAs | |
owl:sameAs | |
owl:sameAs | |
drugbank:description |
"
138-08-9
experimental
Naotaka Hamasaki, Hirotaka Kawamura, Norio Ohtsu, Ichiro Nakakoshi, Kikuo Ataka, Kiyosi Oomori, Masahiko Kouno, "Process for preparing monosodium phosphoenolpyruvate." U.S. Patent US4874882, issued October, 1984.
This compound belongs to the organophosphate esters. These are organic compounds containing phosphoric acid ester functional group.
Organophosphate Esters
Organic Compounds
Organophosphorus Compounds
Organic Phosphoric Acids and Derivatives
Organophosphate Esters
Organic Phosphoric Acids
Enones
Polyamines
Enolates
Carboxylic Acids
enone
enolate
polyamine
carboxylic acid
carboxylic acid derivative
logP
-1.2
ALOGPS
logS
-1.1
ALOGPS
Water Solubility
1.32e+01 g/l
ALOGPS
logP
-0.64
ChemAxon
IUPAC Name
2-(phosphonooxy)prop-2-enoic acid
ChemAxon
Traditional IUPAC Name
phosphoenolpyruvate
ChemAxon
Molecular Weight
168.042
ChemAxon
Monoisotopic Weight
167.982374404
ChemAxon
SMILES
OC(=O)C(=C)OP(O)(O)=O
ChemAxon
Molecular Formula
C3H5O6P
ChemAxon
InChI
InChI=1S/C3H5O6P/c1-2(3(4)5)9-10(6,7)8/h1H2,(H,4,5)(H2,6,7,8)
ChemAxon
InChIKey
InChIKey=DTBNBXWJWCWCIK-UHFFFAOYSA-N
ChemAxon
Polar Surface Area (PSA)
104.06
ChemAxon
Refractivity
30.13
ChemAxon
Polarizability
11.57
ChemAxon
Rotatable Bond Count
3
ChemAxon
H Bond Acceptor Count
5
ChemAxon
H Bond Donor Count
3
ChemAxon
pKa (strongest acidic)
0.76
ChemAxon
Physiological Charge
-3
ChemAxon
Number of Rings
0
ChemAxon
Bioavailability
1
ChemAxon
Rule of Five
true
ChemAxon
ChEBI
26055
PubChem Compound
1005
PubChem Substance
46506098
KEGG Compound
C00074
ChemSpider
980
PDB
PEP
Wikipedia
Phosphoenolpyruvate
SMP00560
Phosphoenolpyruvate carboxykinase deficiency 1 (PEPCK1)
DB00119
Pyruvic acid
DB00121
Biotin
DB01709
2-Phosphoglyceric Acid
DB01819
Phosphoenolpyruvate
DB02263
Glyceraldehyde-3-Phosphate
DB04326
1,3-Dihydroxyacetonephosphate
P11168
P35575
O43826
P36871
P06744
P52789
Q96C23
P09467
P04075
P60174
P04406
Q8TE04
P15259
P06733
P07738
P18669
P35558
P40926
Q02978
P11498
Q9Y5U8
Q6ZMR3
SMP00562
Fructose-1,6-diphosphatase deficiency
DB00119
Pyruvic acid
DB00121
Biotin
DB01709
2-Phosphoglyceric Acid
DB01819
Phosphoenolpyruvate
DB02263
Glyceraldehyde-3-Phosphate
DB04326
1,3-Dihydroxyacetonephosphate
P11168
P35575
O43826
P36871
P06744
P52789
Q96C23
P09467
P04075
P60174
P04406
Q8TE04
P15259
P06733
P07738
P18669
P35558
P40926
Q02978
P11498
Q9Y5U8
Q6ZMR3
SMP00374
Glycogen Storage Disease Type 1A (GSD1A) or Von Gierke Disease
DB00119
Pyruvic acid
DB00121
Biotin
DB01709
2-Phosphoglyceric Acid
DB01819
Phosphoenolpyruvate
DB02263
Glyceraldehyde-3-Phosphate
DB04326
1,3-Dihydroxyacetonephosphate
P11168
P35575
O43826
P36871
P06744
P52789
Q96C23
P09467
P04075
P60174
P04406
Q8TE04
P15259
P06733
P07738
P18669
P35558
P40926
Q02978
P11498
Q9Y5U8
Q6ZMR3
SMP00240
Salla Disease/Infantile Sialic Acid Storage Disease
DB00119
Pyruvic acid
DB00130
L-Glutamine
DB00141
N-Acetyl-D-glucosamine
DB00142
L-Glutamic Acid
DB01296
Glucosamine
DB01819
Phosphoenolpyruvate
DB02431
Cytidine-5'-Triphosphate
DB03166
Acetic acid
DB03435
Uridine-5'-Diphosphate
Q13231
P06865
Q9UJ70
Q9Y303
Q96EK6
P46926
Q06210
O95394
Q16222
P51606
Q9Y223
P19367
Q9NR45
Q9BXD5
Q8TBE9
Q8NFW8
Q9NRA2
SMP00045
Amino Sugar Metabolism
DB00119
Pyruvic acid
DB00130
L-Glutamine
DB00141
N-Acetyl-D-glucosamine
DB00142
L-Glutamic Acid
DB01296
Glucosamine
DB01819
Phosphoenolpyruvate
DB02431
Cytidine-5'-Triphosphate
DB03166
Acetic acid
DB03435
Uridine-5'-Diphosphate
Q13231
P06865
Q9UJ70
Q9Y303
Q96EK6
P46926
Q06210
O95394
Q16222
P51606
Q9Y223
P19367
Q9NR45
Q9BXD5
Q8TBE9
Q8NFW8
Q9NRA2
SMP00534
G(M2)-Gangliosidosis: Variant B, Tay-sachs disease
DB00119
Pyruvic acid
DB00130
L-Glutamine
DB00141
N-Acetyl-D-glucosamine
DB00142
L-Glutamic Acid
DB01296
Glucosamine
DB01819
Phosphoenolpyruvate
DB02431
Cytidine-5'-Triphosphate
DB03166
Acetic acid
DB03435
Uridine-5'-Diphosphate
Q13231
P06865
Q9UJ70
Q9Y303
Q96EK6
P46926
Q06210
O95394
Q16222
P51606
Q9Y223
P19367
Q9NR45
Q9BXD5
Q8TBE9
Q8NFW8
Q9NRA2
SMP00572
Fanconi-bickel syndrome
DB00119
Pyruvic acid
DB01345
Potassium
DB01709
2-Phosphoglyceric Acid
DB01819
Phosphoenolpyruvate
DB02263
Glyceraldehyde-3-Phosphate
DB04326
1,3-Dihydroxyacetonephosphate
P11168
P52789
Q96C23
P06744
P08237
P04075
P60174
P35575
P04406
P07738
Q8TE04
P18669
P15259
P06733
P30613
SMP00212
Pyruvate Dehydrogenase Complex Deficiency
DB00119
Pyruvic acid
DB00121
Biotin
DB00143
Glutathione
DB01345
Potassium
DB01593
Zinc
DB01819
Phosphoenolpyruvate
DB01839
1,2-Propanediol
DB03066
D-Lactic Acid
DB03166
Acetic acid
DB04524
Malonyl-Coenzyme A
P11498
Q6ZMR3
P30613
P35558
P40925
P23368
Q86WU2
Q16775
Q04760
Q9UBQ7
P15121
P48163
P09622
P10515
Q13085
P24752
Q8WYK0
P07311
P05091
Q9NR19
P08559
P11177
SMP00334
Pyruvate Decarboxylase E1 Component Deficiency (PDHE1 Deficiency)
DB00119
Pyruvic acid
DB00121
Biotin
DB00143
Glutathione
DB01345
Potassium
DB01593
Zinc
DB01819
Phosphoenolpyruvate
DB01839
1,2-Propanediol
DB03066
D-Lactic Acid
DB03166
Acetic acid
DB04524
Malonyl-Coenzyme A
P11498
Q6ZMR3
P30613
P35558
P40925
P23368
Q86WU2
Q16775
Q04760
Q9UBQ7
P15121
P48163
P09622
P10515
Q13085
P24752
Q8WYK0
P07311
P05091
Q9NR19
P08559
P11177
SMP00559
Pyruvate kinase deficiency
DB00119
Pyruvic acid
DB00121
Biotin
DB00143
Glutathione
DB01345
Potassium
DB01593
Zinc
DB01819
Phosphoenolpyruvate
DB01839
1,2-Propanediol
DB03066
D-Lactic Acid
DB03166
Acetic acid
DB04524
Malonyl-Coenzyme A
P11498
Q6ZMR3
P30613
P35558
P40925
P23368
Q86WU2
Q16775
Q04760
Q9UBQ7
P15121
P48163
P09622
P10515
Q13085
P24752
Q8WYK0
P07311
P05091
Q9NR19
P08559
P11177
SMP00390
Tay-Sachs Disease
DB00119
Pyruvic acid
DB00130
L-Glutamine
DB00141
N-Acetyl-D-glucosamine
DB00142
L-Glutamic Acid
DB01296
Glucosamine
DB01819
Phosphoenolpyruvate
DB02431
Cytidine-5'-Triphosphate
DB03166
Acetic acid
DB03435
Uridine-5'-Diphosphate
Q13231
P06865
Q9UJ70
Q9Y303
Q96EK6
P46926
Q06210
O95394
Q16222
P51606
Q9Y223
P19367
Q9NR45
Q9BXD5
Q8TBE9
Q8NFW8
Q9NRA2
SMP00531
Glycogenosis, Type VII. Tarui disease
DB00119
Pyruvic acid
DB01345
Potassium
DB01709
2-Phosphoglyceric Acid
DB01819
Phosphoenolpyruvate
DB02263
Glyceraldehyde-3-Phosphate
DB04326
1,3-Dihydroxyacetonephosphate
P11168
P52789
Q96C23
P06744
P08237
P04075
P60174
P35575
P04406
P07738
Q8TE04
P18669
P15259
P06733
P30613
SMP00581
Glycogenosis, Type IA. Von gierke disease
DB00119
Pyruvic acid
DB00121
Biotin
DB01709
2-Phosphoglyceric Acid
DB01819
Phosphoenolpyruvate
DB02263
Glyceraldehyde-3-Phosphate
DB04326
1,3-Dihydroxyacetonephosphate
P11168
P35575
O43826
P36871
P06744
P52789
Q96C23
P09467
P04075
P60174
P04406
Q8TE04
P15259
P06733
P07738
P18669
P35558
P40926
Q02978
P11498
Q9Y5U8
Q6ZMR3
SMP00654
Warburg Effect
DB00119
Pyruvic acid
DB00121
Biotin
DB00130
L-Glutamine
DB00139
Succinic acid
DB00142
L-Glutamic Acid
DB01345
Potassium
DB01677
Fumarate
DB01709
2-Phosphoglyceric Acid
DB01819
Phosphoenolpyruvate
DB02263
Glyceraldehyde-3-Phosphate
DB04272
Citric Acid
DB04326
1,3-Dihydroxyacetonephosphate
P11168
P52789
P06744
P17858
P05062
P04406
P00558
P15259
P06733
P30613
Q9Y5U8
P11498
P08559
P11177
P10515
P09622
O75390
Q6ZMR3
P53985
Q99798
P50213
O43837
P51553
Q02218
P36957
P53597
Q96I99
P31040
P21912
Q99643
O14521
P07954
P40925
P00367
Q9UI32
Q15758
P37837
P29401
P49247
O95336
P11413
P52209
Q6LAP8
P21399
O75874
P14618
SMP00216
Sialuria or French Type Sialuria
DB00119
Pyruvic acid
DB00130
L-Glutamine
DB00141
N-Acetyl-D-glucosamine
DB00142
L-Glutamic Acid
DB01296
Glucosamine
DB01819
Phosphoenolpyruvate
DB02431
Cytidine-5'-Triphosphate
DB03166
Acetic acid
DB03435
Uridine-5'-Diphosphate
Q13231
P06865
Q9UJ70
Q9Y303
Q96EK6
P46926
Q06210
O95394
Q16222
P51606
Q9Y223
P19367
Q9NR45
Q9BXD5
Q8TBE9
Q8NFW8
Q9NRA2
SMP00128
Gluconeogenesis
DB00119
Pyruvic acid
DB00121
Biotin
DB01709
2-Phosphoglyceric Acid
DB01819
Phosphoenolpyruvate
DB02263
Glyceraldehyde-3-Phosphate
DB04326
1,3-Dihydroxyacetonephosphate
P11168
P35575
O43826
P36871
P06744
P52789
Q96C23
P09467
P04075
P60174
P04406
Q8TE04
P15259
P06733
P07738
P18669
P35558
P40926
Q02978
P11498
Q9Y5U8
Q6ZMR3
SMP00574
Glycogenosis, Type IC
DB00119
Pyruvic acid
DB00121
Biotin
DB01709
2-Phosphoglyceric Acid
DB01819
Phosphoenolpyruvate
DB02263
Glyceraldehyde-3-Phosphate
DB04326
1,3-Dihydroxyacetonephosphate
P11168
P35575
O43826
P36871
P06744
P52789
Q96C23
P09467
P04075
P60174
P04406
Q8TE04
P15259
P06733
P07738
P18669
P35558
P40926
Q02978
P11498
Q9Y5U8
Q6ZMR3
SMP00573
Glycogenosis, Type IB
DB00119
Pyruvic acid
DB00121
Biotin
DB01709
2-Phosphoglyceric Acid
DB01819
Phosphoenolpyruvate
DB02263
Glyceraldehyde-3-Phosphate
DB04326
1,3-Dihydroxyacetonephosphate
P11168
P35575
O43826
P36871
P06744
P52789
Q96C23
P09467
P04075
P60174
P04406
Q8TE04
P15259
P06733
P07738
P18669
P35558
P40926
Q02978
P11498
Q9Y5U8
Q6ZMR3
SMP00040
Glycolysis
DB00119
Pyruvic acid
DB01345
Potassium
DB01709
2-Phosphoglyceric Acid
DB01819
Phosphoenolpyruvate
DB02263
Glyceraldehyde-3-Phosphate
DB04326
1,3-Dihydroxyacetonephosphate
P11168
P52789
Q96C23
P06744
P08237
P04075
P60174
P35575
P04406
P07738
Q8TE04
P18669
P15259
P06733
P30613
SMP00558
Primary hyperoxaluria II, PH2
DB00119
Pyruvic acid
DB00121
Biotin
DB00143
Glutathione
DB01345
Potassium
DB01593
Zinc
DB01819
Phosphoenolpyruvate
DB01839
1,2-Propanediol
DB03066
D-Lactic Acid
DB03166
Acetic acid
DB04524
Malonyl-Coenzyme A
P11498
Q6ZMR3
P30613
P35558
P40925
P23368
Q86WU2
Q16775
Q04760
Q9UBQ7
P15121
P48163
P09622
P10515
Q13085
P24752
Q8WYK0
P07311
P05091
Q9NR19
P08559
P11177
SMP00563
Triosephosphate isomerase
DB00119
Pyruvic acid
DB00121
Biotin
DB01709
2-Phosphoglyceric Acid
DB01819
Phosphoenolpyruvate
DB02263
Glyceraldehyde-3-Phosphate
DB04326
1,3-Dihydroxyacetonephosphate
P11168
P35575
O43826
P36871
P06744
P52789
Q96C23
P09467
P04075
P60174
P04406
Q8TE04
P15259
P06733
P07738
P18669
P35558
P40926
Q02978
P11498
Q9Y5U8
Q6ZMR3
SMP00217
Sjogren Larsson Syndrome
DB00119
Pyruvic acid
DB00130
L-Glutamine
DB00141
N-Acetyl-D-glucosamine
DB00142
L-Glutamic Acid
DB01296
Glucosamine
DB01819
Phosphoenolpyruvate
DB02431
Cytidine-5'-Triphosphate
DB03166
Acetic acid
DB03435
Uridine-5'-Diphosphate
Q13231
P06865
Q9UJ70
Q9Y303
Q96EK6
P46926
Q06210
O95394
Q16222
P51606
Q9Y223
P19367
Q9NR45
Q9BXD5
Q8TBE9
Q8NFW8
Q9NRA2
SMP00196
Leigh Syndrome
DB00119
Pyruvic acid
DB00121
Biotin
DB00143
Glutathione
DB01345
Potassium
DB01593
Zinc
DB01819
Phosphoenolpyruvate
DB01839
1,2-Propanediol
DB03066
D-Lactic Acid
DB03166
Acetic acid
DB04524
Malonyl-Coenzyme A
P11498
Q6ZMR3
P30613
P35558
P40925
P23368
Q86WU2
Q16775
Q04760
Q9UBQ7
P15121
P48163
P09622
P10515
Q13085
P24752
Q8WYK0
P07311
P05091
Q9NR19
P08559
P11177
SMP00060
Pyruvate Metabolism
DB00119
Pyruvic acid
DB00121
Biotin
DB00143
Glutathione
DB01345
Potassium
DB01593
Zinc
DB01819
Phosphoenolpyruvate
DB01839
1,2-Propanediol
DB03066
D-Lactic Acid
DB03166
Acetic acid
DB04524
Malonyl-Coenzyme A
P11498
Q6ZMR3
P30613
P35558
P40925
P23368
Q86WU2
Q16775
Q04760
Q9UBQ7
P15121
P48163
P09622
P10515
Q13085
P24752
Q8WYK0
P07311
P05091
Q9NR19
P08559
P11177
BE0002004
Phospho-2-dehydro-3-deoxyheptonate aldolase, Phe-sensitive
Escherichia coli (strain K12)
# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284
# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423
unknown
Phospho-2-dehydro-3-deoxyheptonate aldolase, Phe-sensitive
Amino acid transport and metabolism
Stereospecific condensation of phosphoenolpyruvate (PEP) and D-erythrose-4-phosphate (E4P) giving rise to 3-deoxy-D- arabino-heptulosonate-7-phosphate (DAHP)
aroG
None
6.58
38010.0
Escherichia coli (strain K12)
GenBank Gene Database
J01591
GenBank Protein Database
145368
UniProtKB
P0AB91
UniProt Accession
AROG_ECOLI
3-deoxy-D-arabino-heptulosonate 7-phosphate synthase
DAHP synthetase
EC 2.5.1.54
Phospho-2-keto-3-deoxyheptonate aldolase
>Phospho-2-dehydro-3-deoxyheptonate aldolase, Phe-sensitive
MNYQNDDLRIKEIKELLPPVALLEKFPATENAANTVAHARKAIHKILKGNDDRLLVVIGP
CSIHDPVAAKEYATRLLALREELKDELEIVMRVYFEKPRTTVGWKGLINDPHMDNSFQIN
DGLRIARKLLLDINDSGLPAAGEFLDMITPQYLADLMSWGAIGARTTESQVHRELASGLS
CPVGFKNGTDGTIKVAIDAINAAGAPHCFLSVTKWGHSAIVNTSGNGDCHIILRGGKEPN
YSAKHVAEVKEGLNKAGLPAQVMIDFSHANSSKQFKKQMDVCADVCQQIAGGEKAIIGVM
VESHLVEGNQSLESGEPLAYGKSITDACIGWEDTDALLRQLANAVKARRG
>1053 bp
ATGAATTATCAGAACGACGATTTACGCATCAAAGAAATCAAAGAGTTACTTCCTCCTGTC
GCATTGCTGGAAAAATTCCCCGCTACTGAAAATGCCGCGAATACGGTTGCCCATGCCCGA
AAAGCGATCCATAAGATCCTGAAAGGTAATGATGATCGCCTGTTGGTTGTGATTGGCCCA
TGCTCAATTCATGATCCTGTCGCGGCAAAAGAGTATGCCACTCGCTTGCTGGCGCTGCGT
GAAGAGCTGAAAGATGAGCTGGAAATCGTAATGCGCGTCTATTTTGAAAAGCCGCGTACC
ACGGTGGGCTGGAAAGGGCTGATTAACGATCCGCATATGGATAATAGCTTCCAGATCAAC
GACGGTCTGCGTATAGCCCGTAAATTGCTGCTTGATATTAACGACAGCGGTCTGCCAGCG
GCAGGTGAGTTTCTCGATATGATCACCCCACAATATCTCGCTGACCTGATGAGCTGGGGC
GCAATTGGCGCACGTACCACCGAATCGCAGGTGCACCGCGAACTGGCATCAGGGCTTTCT
TGTCCGGTCGGCTTCAAAAATGGCACCGACGGTACGATTAAAGTGGCTATCGATGCCATT
AATGCCGCCGGTGCGCCGCACTGCTTCCTGTCCGTAACGAAATGGGGGCATTCGGCGATT
GTGAATACCAGCGGTAACGGCGATTGCCATATCATTCTGCGCGGCGGTAAAGAGCCTAAC
TACAGCGCGAAGCACGTTGCTGAAGTGAAAGAAGGGCTGAACAAAGCAGGCCTGCCAGCA
CAGGTGATGATCGATTTCAGCCATGCTAACTCGTCCAAACAATTCAAAAAGCAGATGGAT
GTTTGTGCTGACGTTTGCCAGCAGATTGCCGGTGGCGAAAAGGCCATTATTGGCGTGATG
GTGGAAAGCCATCTGGTGGAAGGCAATCAGAGCCTCGAGAGCGGGGAGCCGCTGGCCTAC
GGTAAGAGCATCACCGATGCCTGCATCGGCTGGGAAGATACCGATGCTCTGTTACGTCAA
CTGGCGAATGCAGTAAAAGCGCGTCGCGGGTAA
PF00793
DAHP_synth_1
function
transferase activity
function
transferase activity, transferring alkyl or aryl (other than methyl) groups
function
3-deoxy-7-phosphoheptulonate synthase activity
function
catalytic activity
process
amino acid and derivative metabolism
process
biosynthesis
process
amino acid biosynthesis
process
aromatic amino acid family biosynthesis
process
physiological process
process
metabolism
process
cellular metabolism
process
amino acid metabolism
BE0001394
2-dehydro-3-deoxyphosphooctonate aldolase
Shigella flexneri
# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284
# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423
unknown
2-dehydro-3-deoxyphosphooctonate aldolase
Cell wall/membrane/envelope biogenesis
Phosphoenolpyruvate + D-arabinose 5-phosphate + H(2)O = 2-dehydro-3-deoxy-D-octonate 8-phosphate + phosphate
kdsA
Cytoplasm
None
6.79
30833.0
Shigella flexneri
GenBank Gene Database
AE005674
GenBank Protein Database
24051519
UniProtKB
P0A716
UniProt Accession
KDSA_SHIFL
3-deoxy-D-manno-octulosonic acid 8- phosphate synthetase
EC 2.5.1.55
KDO 8-P synthase
KDO-8-phosphate synthetase
KDOPS
Phospho-2- dehydro-3-deoxyoctonate aldolase
>2-dehydro-3-deoxyphosphooctonate aldolase
MKQKVVSIGDINVANDLPFVLFGGMNVLESRDLAMRICEHYVTVTQKLGIPYVFKASFDK
ANRSSIHSYRGPGLEEGMKIFQELKQTFGVKIITDVHEPSQAQPVADVVDVIQLPAFLAR
QTDLVEAMAKTGAVINVKKPQFVSPGQMGNIVDKFKEGGNEKVILCDRGANFGYDNLVVD
MLGFSIMKKVSGNSPVIFDVTHALQCRDPFGAASGGRRAQVAELARAGMAVGLAGLFIEA
HPDPEHAKCDGPSALPLAKLEPFLKQMKAIDDLVKGFEELDTSK
>855 bp
ATGAAACAAAAAGTGGTTAGCATTGGCGACATCAACGTAGCAAATGACCTGCCGTTCGTA
CTGTTTGGCGGTATGAACGTGCTGGAATCTCGCGATCTGGCGATGCGCATTTGCGAGCAC
TACGTAACTGTGACCCAGAAACTGGGTATCCCTTACGTGTTCAAAGCCTCTTTTGACAAA
GCCAACCGCTCCTCCATCCACTCTTATCGTGGACCGGGCCTGGAAGAAGGGATGAAAATC
TTCCAGGAGTTGAAGCAGACTTTTGGCGTGAAAATTATCACCGACGTTCACGAACCAAGT
CAGGCACAGCCCGTTGCTGATGTCGTGGATGTGATTCAGTTGCCGGCGTTTCTTGCTCGC
CAGACTGACCTGGTTGAAGCCATGGCGAAAACCGGTGCGGTAATTAACGTCAAGAAACCA
CAGTTTGTCAGCCCGGGACAGATGGGTAATATCGTTGATAAATTCAAAGAAGGCGGCAAC
GAAAAAGTGATTCTTTGCGATCGTGGTGCTAACTTCGGCTATGACAACCTGGTTGTCGAT
ATGCTGGGCTTCAGCATTATGAAGAAAGTGTCTGGTAACTCGCCGGTGATTTTCGACGTG
ACCCACGCACTGCAATGCCGCGATCCGTTTGGCGCAGCTTCCGGTGGTCGTCGTGCTCAG
GTGGCTGAGCTGGCACGAGCCGGTATGGCGGTAGGTCTGGCGGGGCTGTTTATTGAAGCG
CATCCGGATCCGGAACATGCGAAATGTGATGGTCCATCCGCGCTGCCGCTGGCTAAACTG
GAACCGTTCCTCAAGCAGATGAAAGCGATTGATGATCTGGTGAAAGGTTTCGAAGAACTG
GATACCAGCAAGTAA
PF00793
DAHP_synth_1
component
intracellular
component
cytoplasm
component
cell
function
transferase activity, transferring alkyl or aryl (other than methyl) groups
function
3-deoxy-8-phosphooctulonate synthase activity
function
catalytic activity
function
transferase activity
process
physiological process
process
metabolism
process
biosynthesis
BE0004460
Beta-enolase
Human
# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284
# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423
# Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10592235
unknown
Beta-enolase
ENO3
Human
UniProtKB
P13929
UniProt Accession
ENOB_HUMAN
BE0002562
Capsule biosynthesis protein
Neisseria meningitidis
unknown
Capsule biosynthesis protein
Cell wall/membrane/envelope biogenesis
synC
None
5.18
38348.0
Neisseria meningitidis
GenBank Gene Database
U40740
UniProtKB
Q57265
UniProt Accession
Q57265_NEIME
SiaC
>Capsule biosynthesis protein
MQNNNEFKIGNRSVGYNHEPLIICEIGINHEGSLKTAFEMVDAAYNAGAEVVKHQTHIVE
DEMSDEAKQVIPGNADVSIYEIMERCALNEEDEIKLKEYVESKGMIFISTPFSRAAALRL
QRMDIPAYKIGSGECNNYPLIKLVASFGKPIILSTGMNSIESIKKSVEIIREAGVPYALL
HCTNIYPTPYEDVRLGGMNDLSEAFPDAIIGLSDHTLDNYACLGAVALGGSILERHFTDR
MDRPGPDIVCSMNPDTFKELKQGAHALKLARGGKKDTIIAGEKPTKDFAFASVVADKDIK
KGELLSGDNLWVKRPGNGDFSVNEYETLFGKVAACNIRKGAQIKKTDIE
>1050 bp
ATGCAAAACAACAACGAATTTAAAATTGGTAATCGTTCAGTAGGTTACAACCACGAACCA
TTGATTATCTGTGAAATCGGCATCAATCATGAAGGCTCTTTAAAAACAGCTTTTGAAATG
GTTGATGCTGCCTATAATGCAGGCGCTGAAGTTGTTAAACATCAAACACACATCGTTGAA
GACGAAATGTCTGATGAGGCCAAACAAGTCATTCCAGGCAATGCAGATGTCTCTATTTAT
GAAATTATGGAACGTTGCGCCCTGAATGAAGAAGATGAGATTAAATTAAAAGAATACGTA
GAGAGTAAGGGTATGATTTTTATCAGTACTCCTTTCTCTCGTGCAGCTGCTTTACGATTA
CAACGTATGGATATTCCAGCATATAAAATCGGCTCTGGCGAATGTAATAACTACCCATTA
ATTAAACTGGTGGCCTCTTTTGGTAAGCCTATTATTCTCTCTACCGGCATGAATTCTATT
GAAAGCATCAAAAAGTCGGTAGAAATTATTCGAGAAGCAGGGGTACCTTATGCTTTGCTT
CACTGTACCAACATCTACCCAACCCCTTACGAAGATGTTCGATTGGGTGGTATGAACGAT
TTATCTGAAGCCTTTCCAGACGCAATCATTGGCCTGTCTGACCATACCTTAGATAACTAT
GCTTGCTTAGGAGCAGTAGCTTTAGGCGGTTCGATTTTAGAGCGTCACTTTACTGACCGC
ATGGATCGCCCAGGTCCGGATATTGTATGCTCTATGAATCCGGATACTTTTAAAGAGCTC
AAGCAAGGCGCTCATGCTTTAAAATTGGCACGCGGCGGCAAAAAAGACACGATTATCGCG
GGAGAAAAGCCAACTAAAGATTTCGCCTTTGCATCTGTCGTAGCAGATAAAGACATTAAA
AAAGGAGAACTGTTGTCCGGAGATAACCTATGGGTTAAACGCCCAGGCAATGGAGACTTC
AGCGTCAACGAATATGAAACATTATTTGGTAAGGTCGCTGCTTGCAATATTCGCAAAGGT
GCTCAAATCAAAAAAACTGATATTGAATAA
PF03102
NeuB
BE0000906
Phosphoenolpyruvate carboxykinase, cytosolic [GTP]
Human
# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284
# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423
unknown
Phosphoenolpyruvate carboxykinase, cytosolic [GTP]
Energy production and conversion
GTP + oxaloacetate = GDP + phosphoenolpyruvate + CO(2)
PCK1
20q13.31
Cytoplasm
None
6.05
69195.0
Human
HUGO Gene Nomenclature Committee (HGNC)
HGNC:8724
GenAtlas
PCK1
GeneCards
PCK1
GenBank Gene Database
L05144
GenBank Protein Database
189945
UniProtKB
P35558
UniProt Accession
PCKGC_HUMAN
EC 4.1.1.32
PEPCK-C
Phosphoenolpyruvate carboxylase
>Phosphoenolpyruvate carboxykinase, cytosolic [GTP]
MPPQLQNGLNLSAKVVQGSLDSLPQAVREFLENNAELCQPDHIHICDGSEEENGRLLGQM
EEEGILRRLKKYDNCWLALTDPRDVARIESKTVIVTQEQRDTVPIPKTGLSQLGRWMSEE
DFEKAFNARFPGCMKGRTMYVIPFSMGPLGSPLSKIGIELTDSPYVVASMRIMTRMGTPV
LEAVGDGEFVKCLHSVGCPLPLQKPLVNNWPCNPELTLIAHLPDRREIISFGSGYGGNSL
LGKKCFALRMASRLAKEEGWLAEHMLILGITNPEGEKKYLAAAFPSACGKTNLAMMNPSL
PGWKVECVGDDIAWMKFDAQGHLRAINPENGFFGVAPGTSVKTNPNAIKTIQKNTIFTNV
AETSDGGVYWEGIDEPLASGVTITSWKNKEWSSEDGEPCAHPNSRFCTPASQCPIIDAAW
ESPEGVPIEGIIFGGRRPAGVPLVYEALSWQHGVFVGAAMRSEATAAAEHKGKIIMHDPF
AMRPFFGYNFGKYLAHWLSMAQHPAAKLPKIFHVNWFRKDKEGKFLWPGFGENSRVLEWM
FNRIDGKASTKLTPIGYIPKEDALNLKGLGHINMMELFSISKEFWEKEVEDIEKYLEDQV
NADLPCEIEREILALKQRISQM
>1869 bp
ATGCCTCCTCAGCTGCAAAACGGCCTGAACCTCTCGGCCAAAGTTGTCCAGGGAAGCCTG
GACAGCCTGCCCCAGGCAGTGAGGGAGTTTCTCGAGAATAACGCTGAGCTGTGTCAGCCT
GATCACATCCACATCTGTGACGGCTCTGAGGAGGAGAATGGGCGGCTTCTGGGCCAGATG
GAGGAAGAGGGCATCCTCAGGCGGCTGAAGAAGTATGACAACTGCTGGTTGGCTCTCACT
GACCCCAGGGATGTGGCCAGGATCGAAAGCAAGACGGTTATCGTCACCCAAGAGCAAAGA
GACACAGTGCCCATCCCCAAAACAGGCCTCAGCCAGCTCGGTCGCTGGATGTCAGAGGAG
GATTTTGAGAAAGCGTTCAATGCCAGGTTCCCAGGGTGCATGAAAGGTCGCACCATGTAC
GTCATCCCATTCAGCATGGGGCCGCTGGGCTCACCTCTGTCGAAGATCGGCATCGAGCTG
ACGGATTCGCCCTACGTGGTGGCCAGCATGCGGATCATGACGCGGATGGGCACGCCCGTC
CTGGAAGCACTGGGCGATGGGGAGTTTGTCAAATGCCTCCATTCTGTGGGGTGCCCTCTG
CCTTTACAAAAGCCTTTGGTCAACAACTGGCCCTGCAACCCGGAGCTGACGCTCATCGCC
CACCTGCCTGACCGCAGAGAGATCATCTCCTTTGGCAGTGGGTACGGCGGGAACTCGCTG
CTCGGGAAGAAGTGCTTTGCTCTCAGGATGGCCAGCCGGCTGGCAGAGGAGGAAGGGTGG
CTGGCAGAGCACATGCTGATTCTGGGTATAACCAACCCTGAGGGTGAGAAGAAGTACCTG
GCGGCCGCATTTCCCAGCGCCTGCGGGAAGACCAACCTGGCCATGATGAACCCCAGCCTC
CCCGGGTGGAAGGTTGAGTGCGTCGGGGATGACATTGCCTGGATGAAGTTTGACGCACAA
GGTCATTTAAGGGCCATCAACCCAGAAAATGGCTTTTTCGGTGTCGCTCCTGGGACTTCA
GTGAAGACCAACCCCAATGCCATCAAGACCATCCAGAAGAACACAATCTTTACCAATGTG
GCCGAGACCAGCGACGGGGGCGTTTACTGGGAAGGCATTGATGAGCCGCTAGCTTCAGGC
GTCACCATCACGTCCTGGAAGAATAAGGAGTGGAGCTCAGAGGATGGGGAACCTTGTGCC
CACCCCAACTCGAGGTTCTGCACCCCTGCCAGCCAGTGCCCCATCATTGATGCTGCCTGG
GAGTCTCCGGAAGGTGTTCCCATTGAAGGCATTATCTTTGGAGGCCGTAGACCTGCTGGT
GTCCCTCTAGTCTATGAAGCTCTCAGCTGGCAACATGGAGTCTTTGTGGGGGCGGCCATG
AGATCAGAGGCCACAGCGGCTGCAGAACATAAAGGCAAAATCATCATGCATGACCCCTTT
GCCATGCGGCCCTTCTTTGGCTACAACTTCGGCAAATACCTGGCCCACTGGCTTAGCATG
GCCCAGCACCCAGCAGCCAAACTGCCCAAGATCTTCCATGTCAACTGGTTCCGGAAGGAC
AAGGAAGGCAAATTCCTCTGGCCAGGCTTTGGAGAGAACTCCAGGGTGCTGGAGTGGATG
TTCAACCGGATCGATGGAAAAGCCAGCACCAACGTCACGCCCATAGGCTACATCCCCAAG
GAGGATGCCCTGAACCTGAAAGGCCTGGGGCACATCAACATGATGGAGCTTTTCAGCATC
TCCAAGGAATTCTGGGACAAGGAGGTGGAAGACATCGAGAAGTATCTGGTGGATCAAGTC
AATGCCGACCTCCCCTGTGAAATCGAGAGAGAGATCCTTGCCTTGAAGCAAAGAATAAGC
CAGATGTAA
PF00821
PEPCK
function
carbon-carbon lyase activity
function
phosphoenolpyruvate carboxykinase activity
function
carboxy-lyase activity
function
nucleotide binding
function
purine nucleotide binding
function
guanyl nucleotide binding
function
binding
function
GTP binding
function
catalytic activity
function
lyase activity
process
physiological process
process
alcohol metabolism
process
monosaccharide metabolism
process
metabolism
process
hexose metabolism
process
cellular metabolism
process
glucose metabolism
process
gluconeogenesis
BE0001253
2-dehydro-3-deoxyphosphooctonate aldolase
Aquifex aeolicus (strain VF5)
# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284
# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423
unknown
2-dehydro-3-deoxyphosphooctonate aldolase
Cell wall/membrane/envelope biogenesis
Phosphoenolpyruvate + D-arabinose 5-phosphate + H(2)O = 2-dehydro-3-deoxy-D-octonate 8-phosphate + phosphate
kdsA
Cytoplasm
None
6.68
29735.0
Aquifex aeolicus (strain VF5)
GenBank Gene Database
AE000657
GenBank Protein Database
2982835
UniProtKB
O66496
UniProt Accession
KDSA_AQUAE
3-deoxy-D-manno-octulosonic acid 8- phosphate synthetase
EC 2.5.1.55
KDO 8-P synthase
KDO-8-phosphate synthetase
KDOPS
Phospho-2- dehydro-3-deoxyoctonate aldolase
>2-dehydro-3-deoxyphosphooctonate aldolase
MEKFLVIAGPCAIESEELLLKVGEEIKRLSEKFKEVEFVFKSSFDKANRSSIHSFRGHGL
EYGVKALRKVKEEFGLKITTDIHESWQAEPVAEVADIIQIPAFLCRQTDLLLAAAKTGRA
VNVKKGQFLAPWDTKNVVEKLKFGGAKEIYLTERGTTFGYNNLVVDFRSLPIMKQWAKVI
YDATHSVQLPGGLGDKSGGMREFIFPLIRAAVAVGCDGVFMETHPEPEKALSDASTQLPL
SQLEGIIEAILEIREVASKYYETIPVK
>804 bp
ATGGAAAAGTTTTTAGTGATAGCTGGACCCTGCGCGATAGAGAGCGAGGAACTTCTCCTA
AAGGTAGGGGAGGAGATAAAGCGTTTATCGGAGAAGTTCAAAGAAGTTGAGTTCGTATTT
AAGTCTTCCTTTGATAAAGCGAACCGCTCCTCAATACATTCCTTCAGGGGGCACGGTCTT
GAATACGGGGTAAAGGCTCTGAGGAAGGTAAAGGAAGAGTTCGGACTGAAGATTACCACG
GATATTCACGAGAGCTGGCAAGCTGAACCAGTTGCAGAAGTTGCGGACATAATCCAGATA
CCTGCCTTTTTATGCAGGCAGACTGACCTCCTCCTTGCGGCTGCAAAAACGGGAAGGGCT
GTAAACGTGAAGAAGGGTCAGTTTTTAGCCCCTTGGGACACGAAGAACGTGGTTGAAAAA
TTAAAGTTCGGCGGTGCTAAGGAGATATACCTCACGGAGAGAGGAACTACCTTCGGATAC
AACAACCTCGTTGTAGATTTCAGGAGCCTACCCATAATGAAACAGTGGGCAAAGGTTATA
TACGACGCCACCCACAGCGTCCAGCTCCCCGGAGGTCTCGGGGACAAATCAGGAGGAATG
AGGGAGTTTATATTCCCCTTAATCCGTGCTGCGGTTGCGGTAGGTTGTGACGGTGTGTTT
ATGGAAACACACCCAGAACCAGAAAAGGCACTCTCGGACGCATCAACTCAGCTTCCCCTC
TCCCAGCTGGAAGGGATAATAGAGGCTATCCTTGAGATAAGGGAAGTGGCTTCAAAGTAT
TACGAAACAATTCCCGTTAAATGA
PF00793
DAHP_synth_1
component
cell
component
intracellular
component
cytoplasm
function
transferase activity
function
transferase activity, transferring alkyl or aryl (other than methyl) groups
function
3-deoxy-8-phosphooctulonate synthase activity
function
catalytic activity
process
metabolism
process
biosynthesis
process
physiological process
BE0001721
Phospho-2-dehydro-3-deoxyheptonate aldolase
Thermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099)
# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284
# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423
unknown
Phospho-2-dehydro-3-deoxyheptonate aldolase
Amino acid transport and metabolism
Catalyzes the condensation of phosphoenolpyruvate (PEP) and D-erythrose-4-phosphate (E4P) giving rise to 3-deoxy-D- arabino-heptulosonate-7-phosphate (DAHP)
aroF
None
6.64
37379.0
Thermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099)
GenBank Gene Database
AE000512
GenBank Protein Database
4980844
UniProtKB
Q9WYH8
UniProt Accession
AROF_THEMA
3-deoxy-D-arabino- heptulosonate 7-phosphate synthase
DAHP synthetase
EC 2.5.1.54
Phospho-2- keto-3-deoxyheptonate aldolase
>Phospho-2-dehydro-3-deoxyheptonate aldolase
MIVVLKPGSTEEDIRKVVKLAESYNLKCHISKGQERTVIGIIGDDRYVVADKFESLDCVE
SVVRVLKPYKLVSREFHPEDTVIDLGDVKIGNGYFTIIAGPCSVEGREMLMETAHFLSEL
GVKVLRGGAYKPRTSPYSFQGLGEKGLEYLREAADKYGMYVVTEALGEDDLPKVAEYADI
IQIGARNAQNFRLLSKAGSYNKPVLLKRGFMNTIEEFLLSAEYIANSGNTKIILCERGIR
TFEKATRNTLDISAVPIIRKESHLPILVDPSHSGGRRDLVIPLSRAAIAVGAHGIIVEVH
PEPEKALSDGKQSLDFELFKELVQEMKKLADALGVKVN
>1017 bp
ATGATAGTCGTTTTGAAACCCGGTTCCACAGAAGAAGATATAAGGAAGGTGGTGAAGTTG
GCCGAGAGTTACAACTTGAAGTGTCACATTTCCAAAGGTCAGGAAAGAACGGTTATTGGG
ATCATCGGGGACGACAGGTACGTGGTGGCGGACAAGTTCGAGTCGCTGGATTGCGTGGAA
AGCGTTGTGAGGGTGCTCAAACCTTACAAACTCGTTTCTCGTGAGTTCCATCCGGAGGAC
ACGGTGATCGACCTCGGAGATGTGAAGATAGGAAACGGCTACTTCACCATCATAGCGGGA
CCGTGCTCAGTTGAAGGCAGGGAAATGCTCATGGAAACCGCACACTTTTTAAGCGAACTC
GGTGTTAAAGTTTTGAGGGGAGGGGCCTACAAGCCTCGAACATCTCCTTACTCTTTCCAA
GGACTCGGAGAAAAGGGGCTGGAATACCTGAGAGAGGCTGCCGACAAGTACGGTATGTAC
GTGGTGACGGAGGCTCTCGGAGAAGACGATCTTCCAAAAGTGGCCGAGTACGCTGATATC
ATTCAGATAGGAGCGAGAAACGCTCAGAACTTCAGATTGCTCTCTAAAGCGGGAAGCTAC
AACAAACCCGTTCTTCTGAAAAGGGGTTTCATGAACACCATCGAAGAGTTCCTTCTCTCC
GCTGAATACATTGCAAACTCTGGAAACACGAAGATCATACTGTGTGAAAGGGGAATCAGA
ACGTTCGAAAAGGCCACGAGGAACACACTCGATATATCCGCTGTTCCTATAATCAGAAAG
GAATCCCATCTTCCCATTCTGGTGGATCCGAGCCACTCTGGGGGAAGAAGAGACCTCGTT
ATTCCACTCTCCCGGGCCGCTATAGCGGTTGGAGCTCATGGAATCATTGTGGAGGTTCAT
CCGGAGCCGGAGAAGGCACTTTCGGATGGAAAACAGAGTCTTGACTTCGAGCTCTTCAAG
GAACTGGTTCAGGAAATGAAGAAACTCGCTGATGCCCTGGGGGTGAAGGTGAATTGA
PF00793
DAHP_synth_1
function
carbon-carbon lyase activity
function
aldehyde-lyase activity
function
catalytic activity
function
lyase activity
process
amino acid metabolism
process
amino acid and derivative metabolism
process
biosynthesis
process
amino acid biosynthesis
process
physiological process
process
aromatic amino acid family biosynthesis
process
metabolism
process
cellular metabolism
BE0003655
Solute carrier organic anion transporter family member 2A1
Human
inhibitor
# Chan BS, Endo S, Kanai N, Schuster VL: Identification of lactate as a driving force for prostanoid transport by prostaglandin transporter PGT. Am J Physiol Renal Physiol. 2002 Jun;282(6):F1097-102. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11997326
unknown
Solute carrier organic anion transporter family member 2A1
Involved in lipid transporter activity
May mediate the release of newly synthesized prostaglandins from cells, the transepithelial transport of prostaglandins, and the clearance of prostaglandins from the circulation. Transports PGD2, as well as PGE1, PGE2 and PGF2A
SLCO2A1
3q21
Membrane
27-47
71-91
101-121
172-192
210-230
258-278
328-348
366-386
400-420
511-531
551-571
606-626
8.95
70043.3
Human
HUGO Gene Nomenclature Committee (HGNC)
GNC:10955
GeneCards
SLCO2A1
GenBank Gene Database
U70867
GenBank Protein Database
1617590
UniProtKB
Q92959
UniProt Accession
SO2A1_HUMAN
PGT
Prostaglandin transporter
Solute carrier family 21 member 2
>Solute carrier organic anion transporter family member 2A1
MGLLPKLGASQGSDTSTSRAGRCARSVFGNIKVFVLCQGLLQLCQLLYSAYFKSSLTTIE
KRFGLSSSSSGLISSLNEISNAILIIFVSYFGSRVHRPRLIGIGGLFLAAGAFILTLPHF
LSEPYQYTLASTGNNSRLQAELCQKHWQDLPPSKCHSTTQNPQKETSSMWGLMVVAQLLA
GIGTVPIQPFGISYVDDFSEPSNSPLYISILFAISVFGPAFGYLLGSVMLQIFVDYGRVN
TAAVNLVPGDPRWIGAWWLGLLISSALLVLTSFPFFFFPRAMPIGAKRAPATADEARKLE
EAKSRGSLVDFIKRFPCIFLRLLMNSLFVLVVLAQCTFSSVIAGLSTFLNKFLEKQYGTS
AAYANFLIGAVNLPAAALGMLFGGILMKRFVFSLQAIPRIATTIITISMILCVPLFFMGC
STPTVAEVYPPSTSSSIHPQSPACRRDCSCPDSIFHPVCGDNGIEYLSPCHAGCSNINMS
SATSKQLIYLNCSCVTGGSASAKTGSCPVPCAHFLLPAIFLISFVSLIACISHNPLYMMV
LRVVNQEEKSFAIGVQFLLMRLLAWLPSPALYGLTIDHSCIRWNSLCLGRRGACAYYDND
ALRDRYLGLQMGYKALGMLLLCFISWRVKKNKEYNVQKAAGLI
>1932 bp
ATGGGGCTCCTGCCCAAGCTCGGCGTGTCCCAGGGCAGCGACACCTCTACTAGCCGAGCC
GGCCGCTGTGCCCGCTCGGTCTTCGGCAACATTAAGGTGTTTGTGCTCTGCCAAGGCCTC
CTGCAGCTCTGCCAACTCCTGTACAGCGCCTACTTCAAGAGCAGCCTCACCACCATTGAG
AAGCGCTTTGGGCTCTCCAGTTCTTCATCGGGTCTCATTTCCAGCTTGAATGAGATCAGC
AATGCCATCCTCATCATCTTTGTCAGCTACTTTGGCAGCCGGGTGCACCGTCCACGTCTG
ATTGGCATCGGAGGTCTCTTCCTGGCTGCAGGTGCCTTCATCCTCACCCTCCCACACTTC
CTCTCCGAGCCCTACCAGTACACCTTGGCCAGCACTGGGAACAACAGCCGCTTGCAGGCC
GAGCTCTGCCAGAAGCATTGGCAGGACCTGCCTCCCAGTAAGTGCCACAGCACCACCCAG
AACCCCCAGAAGGAGACCAGCAGCATGTGGGGCCTGATGGTGGTTGCCCAGCTGCTGGCT
GGCATCGGGACAGTGCCTATTCAGCCATTTGGGATCTCCTATGTGGATGACTTCTCAGAG
CCCAGCAACTCGCCCCTGTACATCTCCATCTTATTTGCCATCTCTGTATTTGGACCGGCT
TTCGGGTACCTGCTGGGCTCTATCATGCTGCAGATCTTTGTGGACTATGGCAGGGTCAAC
ACAGCTGCAGTTAACTTGGTCCCGGGTGACCCCCGATGGATTGGAGCCTGGTGGCTAGGC
CTGCTCATTTCTTCAGCTTTATTGGTTCTCACCTCTTTCCCCTTTTTTTTCTTCCCTCGA
GCAATGCCCATAGGAGCAAAGAGGGCTCCTGCCACAGCAGATGAAGCAAGGAAGTTGGAG
GAGGCCAAGTCAAGAGGCTCCCTGGTGGATTTCATTAAACGGTTTCCATGCATCTTTCTG
AGGCTCCTGATGAACTCACTCTTCGTCCTGGTGGTCCTGGCCCAGTGCACCTTCTCCTCC
GTCATTGCTGGCCTCTCCACCTTCCTCAACAAGTTCCTGGAGAAGCAGTATGGCACCTCA
GCAGCCTATGCCAACTTCCTCATTGGTGCTGTGAACCTCCCTGCTGCAGCCTTGGGGATG
CTGTTTGGAGGAATCCTCATGAAGCGCTTTGTTTTCTCTCTACAAACCATTCCCCGCATA
GCTACCACCATCATCACCATCTCCATGATCCTTTGTGTTCCTTTGTTCTTCATGGGATGC
TCCACCCCAACTGTGGCCGAAGTCTACCCCCCTAGCACATCAAGTTCTATACATCCGCAG
TCTCCTGCCTGCCGCAGGGACTGCTCGTGCCCAGATTCTATCTTCCACCCGGTCTGTGGA
GACAATGGAATCGAGTACCTCTCCCCTTGCCATGCCGGCTGCAGCAACATCAACATGAGC
TCTGCAACCTCCAAGCAACTGATCTATTTGAACTGCAGCTGTGTGACCGGGGGATCCGCT
TCAGCAAAGACAGGATCGTGCCCTGTCCCCTGTGCCCACTTCCTGCTCCCGGCCATCTTC
CTCATCTCCTTCGTGTCCCTGATAGCCTGCATCTCCCACAACCCCCTCTACATGATGGTT
CTGCGTGTGGTGAACCAGGAGGAAAAGTCATTTGCCATCGGGGTGCAGTTCTTGTTGATG
CGCTTGCTGGCCTGGCTGCCATCTCCAGCCCTCTATGGCCTCACCATTGACCACTCCTGC
ATCCGGTGGAACTCGCTGTGCTTGGGGAGGCGAGGGGCCTGCGCCTACTATGACAACGAT
GCTCTCCGAGACAGGTACCTGGGCCTGCAGATGGGCTACAAGGCGCTGGGCATGCTGCTG
CTTTGCTTCATCAGCTGGAGGGTGAAGAAGAACAAGGAGTACAACGTGCAGAAGGCGGCA
GGCCTCATCTGA
PF07648
Kazal_2
PF03137
OATP
component
cell
component
membrane
function
transporter activity
process
physiological process
process
cellular physiological process
process
transport
"
|
owl:sameAs | |
owl:sameAs |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines2/drugbank_small.nt
The resource appears as object in 22 triples